Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 5 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 12098215

    Fusion protein construct

    Northwestern University · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  2. US 12090227

    Method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion

    STANDARD FOODS (CHINA) CO., LTD · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  3. US 12090145

    Combination therapy for treating or preventing depression or other mood diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  4. US 12091440

    IL2 and peptide-MHC complex fusion proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  5. US 12091675

    Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  6. US 12077772

    Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  7. US 12076397

    Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  8. US 12077563

    Prefusion-stabilized hMPV F proteins

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  9. US 12077502

    Formulations of T-type calcium channel modulators and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  10. US 12071516

    Polymeric stabilizing formulations

    Nano Precision Medical, Inc. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  11. US 12060566

    Self-inactivating lentiviral vector comprising a FOXP3 expression cassette

    The Regents of the University of California · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  12. US 12054501

    Compositions and methods for inhibiting arginase activity

    Precision Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  13. US 12054718

    RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  14. US 12053519

    HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  15. US 12043831

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  16. US 12042510

    Modulators of IRF4 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  17. US 12037410

    Methods and compositions for targeting Treg cells

    PRECISION BIOLOGICS, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  18. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  19. US 12029577

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  20. US 12031133

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  21. US 12030958

    Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides

    The Regents of the University of Colorado · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  22. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  23. US 12016932

    Gene editing for hemophilia A with improved factor VIII expression

    CRISPR THERAPEUTICS AG · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  24. US 2024197727

    SOLID DISPERSIONS COMPRISING AMORPHOUS PIMOBENDAN AND ONE OR MORE STABILIZING POLYMERS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Jun 20, 2024 · Expires Jun 15, 2044

    granted